ArchiMed acquires majority stake in NAMSA

Private equity firm ArchiMed acquired a majority stake in NAMSA, a medical device testing CRO, from the Gorski Family. The price was undisclosed.

“Investment from a strategic partner is essential for NAMSA’s next era of growth.”biospace.com

• 1 source
• biospace.comPartnering with Existing Owners and Management, ArchiMed Acquires Majority Interest in NAMSA, the World Leader in Medical Device Testing - BioSpaceAnnalee ArmstrongSep 1, 2020

Summarized from public sources; check the original articles before acting on it.